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Abstract 
Background: Invasive pulmonary aspergillosis (IPA) is an increasingly recognized complication in intensive care unit 
(ICU) patients, especially those with influenza, cirrhosis, chronic obstructive pulmonary disease, and other diseases. 
The diagnosis can be challenging, especially in the ICU, where clinical symptoms as well as imaging are mostly non-
specific. Recently, Aspergillus lateral flow tests were developed to decrease the time to diagnosis of IPA. Several studies 
have shown promising results in bronchoalveolar lavage fluid (BALf ) from hematology patients. We therefore evalu-
ated a new lateral flow test for IPA in ICU patients.
Methods: Using left-over BALf from adult ICU patients in two university hospitals, we studied the performance of 
the Aspergillus galactomannan lateral flow assay (LFA) by IMMY (Norman, OK, USA). Patients were classified according 
to the 2008 EORTC-MSG definitions, the AspICU criteria, and the modified AspICU criteria, which incorporate galac-
tomannan results. These internationally recognized consensus definitions for the diagnosis of IPA incorporate patient 
characteristics, microbiology and radiology. The LFA was read out visually and with a digital reader by researchers 
blinded to the final clinical diagnosis and IPA classification.
Results: We included 178 patients, of which 55 were classified as cases (6 cases of proven and 26 cases of probable 
IPA according to the EORTC-MSG definitions, and an additional 23 cases according to the modified AspICU criteria). 
Depending on the definitions used, the sensitivity of the LFA was 0.88–0.94, the specificity was 0.81, and the area 
under the ROC curve 0.90–0.94, indicating good overall test performance.
Conclusions: In ICU patients, the LFA performed well on BALf and can be used as a rapid screening test while wait-
ing for other microbiological results.
Keywords: Invasive aspergillosis, Diagnosis, Lateral flow assay, Galactomannan
© The Author(s) 2020. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which 
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the 
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or 
other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line 
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory 
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this 
licence, visit http://creat iveco mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco 
mmons .org/publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction
Invasive pulmonary aspergillosis (IPA) is increasingly 
being recognized as an important complication in inten-
sive care unit (ICU) patients, especially in patients with 
severe influenza infection, liver cirrhosis, or chronic 
obstructive pulmonary disease (COPD) [1–3]. More 
recently, patients with coronavirus viral disease 2019 
(COVID-19) also appeared to be at an increased risk for 
IPA [4, 5]. However, the diagnosis can be challenging and 
demands a specific workup as radiologic signs are less 
typical in non-neutropenic patients, and clinical signs 
are non-specific [3]. This becomes apparent in autopsy 
series from ICU patients, where IPA remains one of the 
most commonly missed diagnoses [6, 7]. A recent retro-
spective study found a post-mortem diagnosis of IPA in 
25 (2.8%) of the 893 autopsies performed between 1991 
and 2016 in critically ill patients [7]. As a delay in anti-
fungal treatment is correlated with a significantly higher 
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mortality, these diagnostic difficulties can lead to worse 
outcomes [10].
The only indisputable way of making a “proven” diag-
nosis of IPA is through a biopsy showing Aspergillus 
hyphae (either pre- or post-mortem). Unfortunately, 
a biopsy is not feasible in the majority of ICU patients. 
Because of these diagnostic difficulties, international 
consensus definitions for the diagnosis of IPA for 
research purposes were developed, such as the Euro-
pean Organization for Research and Treatment of Can-
cer/Invasive Fungal Infections Cooperative Group and 
the National Institute of Allergy and Infectious Diseases 
Mycoses Study Group (EORTC/MSG) definitions. The 
use of consensus definitions (in the absence of a useable 
gold standard) has been accepted by regulatory body 
such as the FDA and EMA, both for treatment studies as 
well as for diagnostic studies. However, these definitions 
have mainly been developed for use in immunocompro-
mised patients [8]. Indeed, in an evaluation of a clinical 
algorithm for the diagnosis of IPA developed specifically 
for use in ICU patients, 84% of cases could not be classi-
fied using the EORTC/MSG definitions [9]. For this rea-
son, disease definitions targeting ICU populations were 
recently developed by Blot et al. in the AspICU study, and 
later modified by Schauwvlieghe et  al. [1, 9]. The origi-
nal AspICU criteria, developed by Blot et al., were modi-
fied as the original criteria require a positive culture for 
Aspergillus as entry criterion, even though cultures are 
negative in a large majority of cases [10]. In summary, 
the modified AspICU criteria eliminate the require-
ment of a positive culture and incorporate galactoman-
nan (GM) as a sufficient mycological criterion, and allow 
the inclusion of patients with high-risk diseases such as 
influenza or COPD, that do not have any “classical” host 
factors such as neutropenia. Detection of GM, an anti-
gen that is present in the cell wall of Aspergillus, by the 
Platelia™ enzyme immunoassay, is widely used as a diag-
nostic tool in IPA. The sensitivity and specificity of GM 
detection in bronchoalveolar lavage fluid (BALf) ranges 
between 0.61–0.92, and 0.89–0.98, respectively [11–13]. 
This makes it more sensitive than direct microscopy, fun-
gal culture, or serum GM detection [14]. The variation in 
performance depends on the use of different cut-off val-
ues, the population being tested, or the case definition 
that is used in the study [11–13]. It is important to note 
that these diagnostic characteristics were mainly derived 
from studies that almost exclusively included patients 
with an underlying hematological disease. In the most 
informative study to date in which 26 cases of biopsy 
proven IPA were included, the sensitivity and specificity 
of BALf GM ≥ 0.5 were 0.88 and 0.87, respectively [14].
However, GM detection using the Platelia™ assay is not 
always available on-site and often has a long turnaround 
time to decrease the per-test cost by batching tests, 
increasing the diagnostic delay [15]. A fast, single sample 
test could therefore decrease diagnostic delay. Further-
more, a single sample test would make the handling of 
samples from patients with a highly contagious disease 
(such as COVID-19) easier.
Recently, two lateral flow tests have been developed 
which could facilitate a rapid diagnosis of IPA on single 
samples. These are the AspLFD lateral flow device (LFD) 
by OLM Diagnostics (Newcastle upon Tyne, UK) and the 
sōna Aspergillus galactomannan lateral flow assay (LFA) 
by IMMY (Norman, OK, USA). These assays can be per-
formed similarly to the widely known pregnancy tests: 
after application of the sample to the sample site, the 
appearance of a line at the control site indicates a valid 
test, and the appearance of a line at the test site indicates 
a positive test result. The results from both lateral flow 
tests are available within 15  min to 1  h after sampling, 
depending on the test and sample used.
A comparative study of both tests in BALf from hema-
tological patients showed that the LFA had a significantly 
higher sensitivity than the LFD (0.83 versus 0.69) [17]. To 
date, only a single study in 133 ICU patients evaluated a 
prototype version of the LFD, showing a sensitivity and 
specificity of 0.80 and 0.81, respectively [18]. No studies 
have evaluated the LFA or the commercialized version of 
the LFD in ICU patients, nor are there any comparative 
studies in this population. Based on the superior results 
of the LFA in previous studies, and because of the lack 
of data in ICU patients—which are often significantly dif-
ferent from hematology patients—we performed a clini-
cal study to evaluate the LFA as a rapid diagnostic test in 
ICU patients at risk for IPA.
Materials and methods
We retrospectively collected BALf samples from patients 
admitted to the ICU in two academic centers (Erasmus 
University Medical Center, Rotterdam, The Netherlands, 
and University Hospitals Leuven, Leuven, Belgium) from 
between 2013 and 2019. Patients could be enrolled if 
they (1) were 18 years of age or older, (2) were admitted 
to the ICU, and (3) had sufficient BALf remaining stored 
at − 20  °C. In order to minimize uncertainty about the 
presence or absence of IPA, we excluded patients (1) 
with EORTC/MSG defined possible invasive fungal dis-
ease, (2) with BALf GM ≥ 0.5 and < 1.0, (3) with positive 
mycological findings (such as GM or culture) that did 
not receive mold-active antifungal therapy and survived, 
(4) with probable or putative IPA in whom subsequent 
autopsy could not reveal any sign of IPA, and (5) that had 
received systemic mold-active treatment ≥ 72  h before 
BALf sampling. For each patient, we collected the follow-
ing data: gender, age, weight, primary underlying disease, 
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mycological results (fungal cultures, direct microscopy, 
and histopathology), autopsy results (if performed), abso-
lute neutrophil count, and survival after diagnosis. Due 
to the retrospective nature of this study on remaining 
fractions of previously collected samples for diagnostic 
purposes, the need for informed consent was waived.
Case definitions
Cases were classified according to the 2008 revised 
EORTC/MSG definitions [8], the AspICU definitions as 
published by Blot et  al. [9], and the modified AspICU 
definitions as published by Schauwvlieghe et  al. [1]. For 
the determination of the diagnostic characteristics, true 
positives (“cases”) were defined as those with proven 
or probable IPA (for the EORTC/MSG definitions), or 
those fulfilling the AspICU or modified AspICU defini-
tions. True negatives (“controls”) had, as defined by the 
inclusion and exclusion criteria, no signs of Aspergillus in 
mycological tests (negative culture, microscopy, and GM) 
or at autopsy, did not receive systemic mold-active ther-
apy, and did not have possible IPA.
BALf testing
All frozen BALf samples were defrosted at room tem-
perature and vortexed briefly. Galactomannan was tested 
using the Platelia™ Aspergillus enzyme immunoassay 
(Bio-Rad, Marnes-la-Coquette, France) in accordance 
with the manufacturer’s instructions. The Aspergillus 
galactomannan lateral flow assay (IMMY, Norman, Okla-
homa, USA) was performed in accordance with the man-
ufacturer’s instructions. Visual readout was performed 
by a single, experienced researcher, blinded to the final 
diagnosis of the patient. The LFA result was confirmed 
objectively using a digital reader (Cube reader, Chem-
bio Diagnostics GmbH, Berlin, Germany), with a result 
of ≥ 0.5 considered as positive. The results returned by 
the reader are a dimensionless value, calibrated by the 
manufacturer to mimic the results from the Platelia™ 
assay, with positive results fixed at a cutoff at 0.5. Unless 
otherwise stated, all analyses in this study use the digital 
result of the test and not the visual result. The LFA was 
provided to us by IMMY; the manufacturer had no role in 
the design of this study, its execution, analysis, interpre-
tation of the data, or decision to publish.
Statistical analysis
To obtain the ability to calculate sensitivity and specific-
ity with a maximum of 12% width of the 95% confidence 
interval, at 80% power and at the 95% confidence inter-
val, we used the summary data previously published by 
Mercier et  al. [17] and Jenks et  al. [19], and calculated 
appropriate sample sizes using the method as described 
by Buderer et al. [20].
Based on the reported pooled sensitivity of 73% and 
pooled specificity of 90%, with an expected prevalence 
of 30% in patients undergoing bronchoscopy for sus-
pected IPA, we estimated a total of 175 patients (122 
cases + 53 controls). We determined the sensitivity, spec-
ificity, positive and negative predictive values (assuming 
a final prevalence of IPA of 30% in patients undergoing 
bronchoscopy for suspected IPA) with their respective 
95% confidence intervals (CI’s) according to each clas-
sification system (EORTC/MSG, AspICU and modified 
AspICU). Cox regression was used to analyze survival as 
a function of LFA intensity or positivity. For comparison 
between the serum GM and the LFA, we used McNe-
mar’s test for pairwise observations. For within group 
comparisons (e.g. neutropenic status or centrum effect), 
we used Fisher’s exact test. Statistical analysis was per-
formed using R v3.6.1 (R Foundation for Statistical Com-
puting, Vienna, Austria).
Results
We included a total of 178 patients in our study. Patient 
characteristics are shown in Table  1. BALf was stored 
for a median of 118.7 weeks before testing (interquartile 
range 32.75–227). All samples had a volume of 600 µL or 
more.
Using the EORTC/MSG definitions, we identified 6 
cases of proven IPA and 26 cases of probable IPA. Using 
Table 1 Patient characteristics
IQR interquartile range, BALf GM bronchoalveolar lavage fluid galactomannan, 
COPD chronic obstructive pulmonary disease
Case Control p
n 55 123
Center = Rotterdam (%) 22 (40.0) 54 (43.9) 0.747
Age, years (median [IQR]) 63 [56, 68] 57 [46, 66] 0.073
Male gender (%) 34 (61.8) 66 (53.7) 0.395
Weight, kg (median [IQR]) 70 [60, 84] 70 [62, 85] 0.910
Underlying disease (%) 0.355
Pulmonary disease 22 (40.0) 59 (52.2)
Hematologic malignancy 9 (16.4) 10 (8.8)
Heart disease 4 (7.3) 10 (8.8)
Liver disease 3 (5.5) 5 (4.4)
Gastrointestinal disease 3 (5.5) 2 (1.8)
Other malignancy 2 (3.6) 9 (8.0)
Other 12 (21.8) 18 (15.9)
Neutropenia (%) 8 (17.0) 7 (5.7) 0.094
Influenza (%) 17 (30.9) 47 (38.2) 0.442
COPD (%) 6 (10.9) 15 (12.2) 1.000
Positive culture (%) 28 (50.9)
Positive microscopy (%) 4 (7.3)
BALf GM (median [IQR]) 4.80 [2.73, 5.68]
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the modified AspICU definitions, we identified an addi-
tional 23 cases fulfilling the criteria, for a total of 55 
cases. Using the AspICU definitions (which has a positive 
culture for A. fumigatus as entry criterion for probable or 
putative IPA), we identified 6 cases of proven IPA and 12 
cases of putative IPA. Of these 55 cases, 51 were treated 
using mold-active antifungal drugs while at the ICU. The 
reason for not initiating therapy (e.g. because of missed 
diagnosis, death, starting of therapy after leaving the ICU, 
stopping of curative therapy, or an alternative diagnosis) 
was not recorded in this study.
The diagnostic characteristics of the LFA for the dif-
ferent disease classifications are shown in Table 2 (digi-
tal readout) and Table  3 (visual readout). Using digital 
readout significantly increased the sensitivity and nega-
tive predictive value compared to visual readout in the 
modified AspICU group (p = 0.008 and 0.044, respec-
tively). Conversely, the specificity and positive predictive 
value were significantly lower when using digital readout 
(p < 0.001 for both). The ROC curves for all three classifi-
cations are shown in Fig. 1. The correlation between GM 
levels and LFA results is shown in Fig. 2.
In patients in which this was performed, serum GM 
was significantly less sensitive than the LFA (0.88 vs 0.33, 
p < 0.001), while serum GM was more specific (1.00 vs 
0.89, p = 0.014).
The sensitivity was not significantly different in neu-
tropenic patients vs non-neutropenic patients (0.75 vs 
0.89, p = 0.267), in patients with hematologic malignancy 
(0.67 vs 0.91, p = 0.078), in patients with COPD (1.00 vs 
0.86, p = 1.000), in patients with influenza (0.94 vs 0.84, 
p = 0.416) or in patients receiving antifungal prophy-
laxis > 72 h before sampling (0.78 vs 0.89, p = 0.321). We 
could not identify any centrum effect on sensitivity or 
specificity (p = 0.491 and p = 1.000, respectively).
The LFA in BALf was not predictive of survival (Fig. 3). 
This effect remained not significant after correcting 
for age, neutropenic status, presence of influenza or 
COPD, and underlying disease, either when used as a 
binary predictor (p = 0.290) or as a continuous predictor 
(p = 0.208).
Discussion
This is the first study to evaluate the performance of the 
LFA in ICU patients. This test could allow a faster diag-
nosis of IPA to be made in ICU patients. Because obtain-
ing a “proven” diagnosis of IPA can often be challenging 
in the ICU population, we also included patients with so-
called probable or putative disease. These patients have 
a very high likelihood of having IPA, although there will 
no doubt be patients that are wrongly classified as having 
(or as not having) IPA. For this reason, we classified each 
patient according to the three most widely used disease 
definitions, to avoid bias and to allow comparison with 
other diagnostic studies. These definitions are used inter-
nationally in both epidemiologic, diagnostic and thera-
peutic studies and allow the creation of homogenous 
diagnostic groups across different studies. In our study of 
Table 2 Diagnostic characteristics (including their 95% confidence interval) of  digital readout of  the  lateral flow assay 
for the different disease definitions
Classification Sensitivity Specificity Negative predictive value Positive predictive value
All Cases EORTC/MSG (n = 155) 0.88 (0.71–0.96) 0.81 (0.73–0.88) 0.94 (0.86–0.97) 0.67 (0.58–0.75)
AspICU (n = 141) 0.94 (0.73–1.00) 0.81 (0.73–0.88) 0.97 (0.84–1.00) 0.68 (0.60–0.76)
modified AspICU (n = 178) 0.87 (0.76–0.95) 0.81 (0.73–0.88) 0.94 (0.88–0.97) 0.67 (0.58–0.75)
Criteria excluding 
galactomannan
EORTC/MSG (n = 140) 1.00 (0.80–1.00) 0.81 (0.73–0.88) 0.96 (0.84–0.99) 0.67 (0.58–0.74)
modified AspICU (n = 152) 0.97 (0.82–1.00) 0.81 (0.73–0.88) 0.98 (0.89–1.00) 0.69 (0.60–0.76)
Table 3 Diagnostic characteristics (including their 95% confidence interval) of  visual readout of  the  lateral flow assay 
for the different disease definitions
Classification Sensitivity Specificity Negative predictive value Positive predictive value
All cases EORTC/MSG (n = 155) 0.81 (0.64–0.93) 0.95 (0.90–0.98) 0.92 (0.85–0.96) 0.88 (0.76–0.94)
AspICU
(n = 141)
0.89 (0.65–0.99) 0.95 (0.90–0.98) 0.95 (0.84–0.99) 0.89 (0.78–0.95)
modified AspICU
(n = 178)
0.75 (0.61–0.85) 0.95 (0.90–0.98) 0.90 (0.85–0.93) 0.87 (0.75–0.94)
Criteria excluding 
galactomannan
EORTC/MSG (n = 140) 0.94 (0.71–1.00) 0.95 (0.90–0.98) 0.97 (0.85–1.00) 0.89 (0.79–0.95)
Modified AspICU (n = 152) 0.86 (0.68–0.96) 0.95 (0.90–0.98) 0.94 (0.87–0.98) 0.88 (0.77–0.94)
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178 patients, of which 55 were classified as cases accord-
ing to the modified AspICU criteria (which include a 
positive culture result for Aspergillus, or GM ≥ 1.0 as a 
mycologic criterion), and 123 as control subjects without 
any microbiological evidence of Aspergillus. The modi-
fied AspICU criteria, developed by Schauwvlieghe et al., 
were used to identify patients admitted to the ICU with 
IPA, but not fulfilling the EORTC/MSG criteria.
In our total study population, we found a good sensi-
tivity of 0.88 and specificity of 0.81. Although 17% of the 
cases were neutropenic at time of diagnosis, the sen-
sitivity of the LFA was not significantly higher in neu-
tropenic patients than in non-neutropenic patients. 
When restricting the cases to only those classified as 
cases by the original AspICU criteria, the sensitivity 
even increased to 0.94. A possible explanation for the 
increased sensitivity in this subgroup is that by definition, 
all of these cases had a positive fungal culture result. Pre-
vious studies have indeed also shown that a positive cul-
ture result is associated with higher LFA intensities [17]. 
Interestingly, the sensitivity in our study was significantly 
higher than that found in a small study on 26 non-neu-
tropenic patients (five of which were ICU patients) with 
IPA according to the original AspICU criteria [21]. It is 
not clear what could explain this difference. When look-
ing purely at cases that were classifiable according to the 
EORTC/MSG definitions in our population, our results 
were similar to a recent study in BALf from hematology 
Fig. 1 ROC curves for digital readout of the lateral flow assay. The dot indicates the cutoff with the highest Youden index
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patients, which found a sensitivity of 0.83 (versus 0.88 
in this ICU population) and a specificity of 0.87 (versus 
0.81 in this ICU population). As the LFA was designed 
to detect GM, and GM is a mycologic criterion, there is 
a risk of incorporation bias. Furthermore, there was a 
strong correlation between GM levels as determined by 
Fig. 2 Correlation of galactomannan and lateral flow assay. Pearson’s r = 0.719 (p < 0.001). a Overview of all subjects. b Zoomed in detail
Fig. 3 Kaplan–Meier survival plot of modified AspICU cases of invasive aspergillosis, stratified by LFA positivity
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the Platelia™ assay and LFA intensity. We therefore ana-
lyzed the performance in a subgroup where GM was 
excluded from the criteria. In this subgroup, we found a 
similar or even improved performance of the LFA, indi-
cating that incorporation bias is unlikely.
Initially, there were concerns over visual interpreta-
tion of the test due to the presence of a weak line at the 
test site [17]. This was overcome by using a digital reader, 
improving both the sensitivity and specificity of the assay 
by eliminating uncertainty over low positive results. 
Since this initial study, the manufacturer of the LFA has 
released a compact digital reader for use with the test 
strip, simplifying and standardizing readout, eliminat-
ing inter-observer variability and allowing exact quan-
tification of the test result. Indeed, in this study, this 
manufacturer-supplied digital reader increased the sensi-
tivity and negative predictive value. However, the speci-
ficity and positive predictive value were decreased when 
using this reader, indicating that in our study, the use of 
reader functions more like a lower test cutoff, rather than 
increasing the overall accuracy.
Our study has several limitations. All samples had 
been frozen until further analysis. However, in a previ-
ous study, we found the GM value to be consistent when 
a new GM measurement was performed. Mold-active 
prophylaxis was a strict exclusion criterion for the con-
trol group to maximize the likelihood of patients not 
having IPA, as prophylaxis can lead to false negative 
microbiologic tests [22]. This exclusion criterion was not 
used in the case group, which could lead to bias. How-
ever, we did not notice a significant relation between false 
negativity and mold-active prophylaxis.
After designing, performing and analyzing this study, 
an update to the EORTC/MSG definitions was published 
in December 2019 [23]. In this update, an additional radi-
ologic sign was added and the cutoff values were defined 
more precisely. This means that patients that fulfill the 
2008 version of these definitions will also fulfill the 2019 
version, provided BALf GM is ≥ 1.0, which is the case in 
our study, by design. However, it is possible that some 
patients that are now classified as ‘unclassifiable’ in our 
study, based on the 2019 version, would become classi-
fied as having probable IPA using the 2019 version. Fur-
thermore, consensus definitions on influenza-associated 
pulmonary aspergillosis (IAPA) were published in June 
2020 [24]. In our study, 31% of the cases had a positive 
influenza test. However, all of these cases fulfilled the 
modified AspICU criteria, thereby also fulfilling these 
new IAPA definitions.
According to the package insert, cross-reactivity can 
occur based on positive results from culture filtrate 
from Candida spp., Coccidioides spp., Paracoccidiodes 
brasiliensis, and Histoplasma spp. Whether this in vitro 
cross-reactivity is clinically relevant, is unclear. One ret-
rospective study found positive LFA results in BALf and 
sputum that grew Scedosporium spp., Fusarium spp., 
Saccharomyces cerevisiae, Candida parapsilosis, and 
Geotrichium spp. in fungal culture [16]. It is not clear if 
this constitutes true cross-reactivity or rather undetected 
co-infection with Aspergillus or another closely related 
fungus.
As this is the first study of this diagnostic test in ICU 
patients, we wanted to differentiate patients with IPA 
as best as possible from those without IPA. We there-
fore excluded patients with a high degree of diagnostic 
uncertainty, as we would not be able to interpret the LFA 
results from these patients unambiguously (i.e. is a nega-
tive LFA in a patient with possible disease a false nega-
tive, or does this indicate that the pulmonary lesion is 
caused by another disease, in which case the LFA result 
is actually a true negative). Once the diagnostic accuracy 
of this test is more clearly defined in different studies, 
patients with possible disease can be included as well in 
an effort to clarify if these patients really do have an inva-
sive fungal infection or not.
In conclusion, the sōna Aspergillus galactomannan 
LFA on BALf appears to be a good diagnostic aid for IPA 
in ICU patients. This fast assay can be particularly useful 
in centers with a long turnaround time for more conven-
tional tests such as the Platelia™ GM assay. Independent 
of the disease definitions used, the LFA provided suf-
ficiently reliable results to be used as a rapid diagnostic 
test awaiting further confirmatory tests such as GM, PCR 
or culture. The latter can strengthen or reject the LFA 
test result and thereby confirm the presence or absence 
of Aspergillus. The LFA could aid in quick clinical deci-
sions in ICU patients which eventually may improve sur-
vival of patients with an invasive Aspergillus infection.
Conclusions
In ICU patients, the LFA performed well on BALf and 
can be used as a rapid screening test while waiting for 
other microbiological results.
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